CG Oncology (NASDAQ: CGON) director receives grant of 9,354 stock options at $56.09

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

CG Oncology director Susan E. Graf received a grant of stock options covering 9,354 shares of common stock. The options have an exercise price of $56.09 per share and expire on June 3, 2036. They vest in 12 equal monthly installments beginning after June 4, 2026, subject to her continuous service, with any remaining unvested portion vesting at the next annual stockholder meeting if that occurs within a year. Following this grant, she holds 9,354 director stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Graf Susan E

Role null

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (right to buy)	9,354	$0.00	--

Holdings After Transaction: Director Stock Option (right to buy) — 9,354 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 9,354 options Exercise price: $56.09 per share Expiration date: June 3, 2036 +2 more

5 metrics

Option grant size 9,354 options Director stock option grant on June 4, 2026

Exercise price $56.09 per share Conversion/exercise price of director stock option

Expiration date June 3, 2036 Option expiration for director stock option grant

Underlying shares 9,354 shares Common stock underlying the director stock option

Post-transaction derivative holdings 9,354 options Total director stock options held after the grant

Key Terms

Director Stock Option (right to buy), Grant, award, or other acquisition, underlying security, vesting, +1 more

5 terms

Director Stock Option (right to buy) financial

"security_title: Director Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

underlying security financial

"underlying_security_title: Common Stock"

vesting financial

"shares of common stock subject to the option vest monthly"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

continuous service financial

"subject to the Reporting Person's continuous service to the Issuer"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/05/2026 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Graf Susan E

(Last)

(First)

(Middle)

C/O CG ONCOLOGY, INC.

3000 PEGASUS PARK DRIVE, SUITE 1640

(Street)

DALLAS

TEXAS

75247

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CG Oncology, Inc. [ CGON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Director Stock Option (right to buy)	$56.09	06/04/2026		A		9,354		⁽¹⁾	06/03/2036	Common Stock	9,354	$0	9,354	D

Explanation of Responses:

1. 1/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date.

	/s/ Joshua F. Patterson, Attorney-in-Fact for Susan Graf	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did CG Oncology (CGON) director Susan E. Graf report in this Form 4?

Susan E. Graf reported receiving a grant of stock options for 9,354 CG Oncology common shares. These director options were awarded at a $56.09 exercise price and represent a compensation-related acquisition rather than an open-market purchase or sale of existing shares.

How many CG Oncology (CGON) shares are covered by Susan E. Graf’s new options?

The new director stock option grant covers 9,354 shares of CG Oncology common stock. This entire amount is reflected as directly held derivative securities, giving her the right to buy those shares if she chooses to exercise the options in the future.

What is the exercise price and expiration date of Susan E. Graf’s CGON stock options?

The options have an exercise price of $56.09 per share and expire on June 3, 2036. This means Graf may choose to buy CG Oncology common shares at $56.09 any time before that expiration date, once the options are vested.

How do Susan E. Graf’s CG Oncology (CGON) options vest over time?

One-twelfth of the total shares under the option vest monthly after June 4, 2026, the grant date. If CG Oncology’s next annual stockholder meeting occurs before the first anniversary, any remaining unvested portion fully vests on that meeting date, subject to her continuous service.

Is Susan E. Graf’s Form 4 transaction a market buy or sell of CGON stock?

The Form 4 shows a grant of director stock options, not an open-market trade. The transaction code is “A”, indicating a grant or award acquisition of derivative securities as compensation, with no reported market purchase or sale of CG Oncology common shares.

How many CG Oncology (CGON) options does Susan E. Graf hold after this grant?

After this reported transaction, Susan E. Graf holds 9,354 director stock options directly. This total reflects the newly granted options and represents her current derivative position from this grant as disclosed in the filing’s post-transaction holdings field.